LA JOLLA, Calif., March 15 /PRNewswire/ -- Business development executives, CEOs, and investors from around the world will gather in two weeks to attend the “11th Annual Pharma & Biotech Licensing Deal-Making Summit.” The organizer, Strategic Research Institute, is pleased to publish the evolving list of attending companies, which appears below. Hundreds of high-level executives are slated to attend, including delegates from:
3M Abgenix Actinium Pharmaceuticals, Inc Allos Therapeutics Altana Pharma US Altea Therapeutics Global Licensing, Amgen Amylin Pharmaceuticals Anadys Pharmaceuticals, Inc. Arizona State University Arizona Technology Enterprises ARYx Therapeutics AstraZeneca Pharmaceuticals LP Bausch & Lomb Baxter AG Bayer HealthCare LLC - Animal Health Div. Bioavailability Systems Biogen Idec Inc. Biolexis BioScience Ventures Bristol-Myers Squibb Brown Rudnick LLP Campbell Alliance Capital Royalty L.P. Catalyst Pharmaceutical Research, LLC Celgene Corporation Chelsea Therapeutics CHL Medical Cleveland Clinic Daiichi Medical Research Daiichi Pharmaceutical Corporation Darier Discovery Partners International Eli Lilly and Company Endo Pharmaceuticals Ernest Gallo Clinic and Research Center Fenwick & West, LLP Flamel Technologies Fortress Investment Group FSC Laboratories Genzyme Corporation Gilead Sciences H.I.G. Capital Henry M. Jackson Foundation Idenix Pharmaceuticals Indevus Pharmaceuticals InterMune ISU ABXIS Co. J.P. Morgan Partners Johnson & Johnson Keck Graduate Institute Ligand Pharmaceuticals Lilly Ventures Louisiana State University Medical College of Wisconsin Research Foundation MedImmune, Inc. VMerck & Co. Merck Research Laboratories MTB Investment Advisors Novartis Pharma AG Ovation Pharmaceuticals Paddock Laboratories Pennside Partners Pfizer Inc Pharmacyclics PLx Pharma Praecis Pharmaceuticals Quintiles Transnational Corporation RCP Diagnostics LLC Roche Molecular Systems sanofi-aventis Group Schering-Plough Corporation SCOLR Pharma, Inc. SGX Pharmaceuticals Somaxon Pharmaceuticals Inc. SR One, A Wholly Owned Subsidiary of GlaxoSmithKline Stanford University School of Medicine TAP Pharmaceutical Products Inc. The Dow Chemical Company McNerney & Partners University of New Mexico Vital Therapies Vrije Universiteit Brussels Watson Pharmaceutical Inc. Wyeth Pharmaceuticals ZS Associates
Speakers include business development executives and investors from Genzyme, Merck, Indevus, sanofi-aventis, Bayer, Novartis, Roche, Pfizer, Schering Plough, Celgene, Abgenix, MedImmune, BiogenIDEC, Amylin, Ligand, Johnson & Johnson, Bristol-Myers Squibb, Eli Lilly, TAP, Wyeth, AstraZeneca, and GlaxoSmithKline, among others.
To request the agenda and/or the preliminary list of attendees, contact the organizer, Mark Alexay of Strategic Research Institute, at malexay@srinstitute.comor at 212.967.0095, extension 251. Executive level Pharma, biotech, diagnostics, technology, medical device, and investor personnel are welcome to attend.
Strategic Research Institute
CONTACT: Mark Alexay of Strategic Research Institute, +1-212-967-0095,ext. 251, malexay@srinstitute.comor
Web site: http://www.srinstitute.com/
